Objective
we intend to develop novel anti-HIV compounds based on structural principle of acyclic nucleotide analogues bearing phosphonate function. Our previous joint studies disclosed several classes of these compounds which exhibit powerful antiviral activity against retroviruses including HIV as well as against DNA viruses causing opportunistic AIDS related infections. Several compounds presently undergo clinical trials in various phases of progress. Synthetic alterations involved in this programme will concentrate mainly on three types of side-chain which were identified in the previous period and will focus on modifications of the heterocyclic bases. Particularly, they will concern systems with cumulated amino functions of various location at the base, diverse basicity and involvement in the heteroaromatic pi-system. We will study systems bearing aminoalkyl groups at the positions 2,6 and 8 of the purine, or C4 and C5 substituents in the pyrimidine ring, bases bear ing secondary and tertiary amino groups as well as quaternary bases, e.g. Nl-substituted pyridinium or nicotinamidinium rings, or derivatives of 2- amino/4-aminonicotinic acid with compensated charges. We also intend to investigate such structures which contain phosphonate-bearing chain linked to carbon instead to nitrogen atom (9-deazapurines, 1-deaapyrimidines).Another topics will concern additional minor modifications of the side chain in the HPMP series: it is intended to prepare adenine, guanine and 2,6-diaminopurine derivatives in which the hydroxyl group at the side chain is replaced by amino, alkylamino, dialkylamino, trialkylammonium function, or alkylthio, alkylsulfenyl and alkylsulfonyl group. Finally, we plan to study prodrugs of the established phosphonates (PMEA, pmpa) with the aim to increase their oral bioavailability and improve their pharmacological parameters. We will explore prodrugs which liberate the target drug by cascade mechanism triggered by specific enzymatic reaction and, also, to develop conjugates which simultaneously liberate another antiviral compound acting by mechanism different from the phosphonates. Particular attention will be paid to esters and amides derived from nitrogen sugars. All novel compounds will be subjected to detailed biological investigation encompassing broadspectrum antiviral and cytostatic evaluation as well as to various in vitro studies with selected enzymes (DNA pol, reverse transcriptase uridine phosphorylase, IMP dehydrogenase, etc.)
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
This project has not yet been classified with EuroSciVoc.
Be the first one to suggest relevant scientific fields and help us improve our classification service
You need to log in or register to use this function
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Data not available
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Coordinator
3000 LOUVAIN / LEUVEN
Belgium
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.